Trial Profile
A Phase 1 Study of Lenalidomide and Ibrutinib in Combination With Rituximab in Relapsed and Refractory CLL and SLL
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 11 Aug 2023 The procedures of MRI, CT, ECG, bone marrow Biopsy and bio-specimen collection have been added to the treatments section.
- 11 Aug 2023 The procedures of MRI, CT, ECG, bone marrow Biopsy and bio-specimen collection have been added to the treatments section.
- 11 Aug 2023 Planned End Date changed from 1 Dec 2017 to 31 Jul 2024.